201 related articles for article (PubMed ID: 37499518)
21. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
22. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis.
Pourhanifeh MH; Mahjoubin-Tehran M; Shafiee A; Hajighadimi S; Moradizarmehri S; Mirzaei H; Asemi Z
IUBMB Life; 2020 Mar; 72(3):314-333. PubMed ID: 31828868
[TBL] [Abstract][Full Text] [Related]
23. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
Hu Q; Wang M; Wang J; Tao Y; Niu T
Oncol Res; 2024; 32(4):753-768. PubMed ID: 38560563
[TBL] [Abstract][Full Text] [Related]
24. A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-κB.
Park GB; Chung YH; Jeong JY; Kim D
Int J Oncol; 2017 May; 50(5):1711-1720. PubMed ID: 28339079
[TBL] [Abstract][Full Text] [Related]
25. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA: important player in the pathobiology of multiple myeloma.
Bi C; Chng WJ
Biomed Res Int; 2014; 2014():521586. PubMed ID: 24991558
[TBL] [Abstract][Full Text] [Related]
27. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L; Lin N; Li Y
Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
[TBL] [Abstract][Full Text] [Related]
28. In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma.
Ghosal S; Banerjee S
Med Oncol; 2022 Feb; 39(5):53. PubMed ID: 35150335
[TBL] [Abstract][Full Text] [Related]
29. An emphasis on the interaction of signaling pathways highlights the role of miRNAs in the etiology and treatment resistance of gastric cancer.
Fathi D; Elballal MS; Elesawy AE; Abulsoud AI; Elshafei A; Elsakka EGE; Ismail A; El-Mahdy HA; Elrebehy MA; Doghish AS
Life Sci; 2023 Jun; 322():121667. PubMed ID: 37023952
[TBL] [Abstract][Full Text] [Related]
30. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.
Rossi M; Amodio N; Di Martino MT; Tagliaferri P; Tassone P; Cho WC
Curr Pharm Biotechnol; 2014; 15(5):459-67. PubMed ID: 24846067
[TBL] [Abstract][Full Text] [Related]
32. Serum miR-30d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway.
Zhu B; Chen H; Zhang X; Pan Y; Jing R; Shen L; Wang X; Ju S; Jin C; Cong H
Int J Oncol; 2018 Nov; 53(5):2131-2144. PubMed ID: 30132507
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs.
Mehdizadeh M; Farhadihosseinabadi B; Nikoonezhad M; Sankanian G; Soleimani M; Sayad A
J Oncol Pharm Pract; 2022 Jan; 28(1):149-158. PubMed ID: 34612744
[TBL] [Abstract][Full Text] [Related]
34. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
[TBL] [Abstract][Full Text] [Related]
35. Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression.
Pang J; Shi Q; Liu Z; He J; Liu H; Lin P; Cui J; Yang J
Haematologica; 2017 Jul; 102(7):1273-1280. PubMed ID: 28360146
[TBL] [Abstract][Full Text] [Related]
36. Aberrant microRNA expression in multiple myeloma.
Dimopoulos K; Gimsing P; Grønbæk K
Eur J Haematol; 2013 Aug; 91(2):95-105. PubMed ID: 23586898
[TBL] [Abstract][Full Text] [Related]
37. The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance.
Chen R; Zhao H; Wu D; Zhao C; Zhao W; Zhou X
Oncotarget; 2016 Nov; 7(45):73101-73113. PubMed ID: 27683032
[TBL] [Abstract][Full Text] [Related]
38. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
Pichiorri F; Suh SS; Ladetto M; Kuehl M; Palumbo T; Drandi D; Taccioli C; Zanesi N; Alder H; Hagan JP; Munker R; Volinia S; Boccadoro M; Garzon R; Palumbo A; Aqeilan RI; Croce CM
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12885-90. PubMed ID: 18728182
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
40. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
